SCHEMBL969461

SCHEMBL969461

O=C(CN1CCn2c(cc3nc(N4CCOCC4)ncc32)C1)N1CCN(C2CCC2)CC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HRH3 Q9Y5N1 4/20 0.37
PIK3CA P42336 1/20 0.36
ADRA1A P35348 2/20 0.36
SIGMAR1 Q99720 4/20 0.36
TLR4 O00206 1/20 0.35
TLR9 Q9NR96 1/20 0.35
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
CYP11B2 P19099 1/20 0.35
CD38 P28907 1/20 0.34
CYP1A2 P05177 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
RECQL P46063 1/20 0.34
PIK3CD O00329 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL968575 0.82 SIGMAR1 (0.38) KDM4EALDH1A1HRH3SIGMAR1HTT
SCHEMBL970851 0.79 SIGMAR1 (0.46) KDM4EALDH1A1HRH3SIGMAR1HTT
SCHEMBL1017235 0.78 HSP90AB1 (0.47) KDM4EALDH1A1HRH3ADRA1A
SCHEMBL967219 0.77 SIGMAR1 (0.47) KDM4EALDH1A1HRH3SIGMAR1
SCHEMBL968574 0.77 SIGMAR1 (0.47) KDM4EALDH1A1HRH3SIGMAR1HTT
SCHEMBL1014897 0.76 HSP90AB1 (0.47) KDM4EALDH1A1PIK3CAADRA1A
SCHEMBL970389 0.76 SIGMAR1 (0.41) KDM4EALDH1A1HRH3SIGMAR1HTT
SCHEMBL971655 0.75 SIGMAR1 (0.47) KDM4EALDH1A1HRH3SIGMAR1
SCHEMBL967841 0.74 KDM4E (0.39) KDM4EALDH1A1HRH3PIK3CAADRA1A
SCHEMBL1017526 0.73 ADRA1A (0.38) KDM4EALDH1A1HRH3PIK3CAADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 KDM4E 3037/4885ALDH1A1 812/4885HRH3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.